Today’s post looks like it is for the contract nerds. It is not. If you sign contracts, negotiate them, or get dragged into the “can’t we just close this?” call, this one is for you. Topic: liability caps . The clause everyone claims is non-negotiable until the moment they negotiate it for four weeks. The clause that somehow manages to be both (i) “market standard” and (ii) the reason your deal has been stuck in legal review since the last ice age.  Everyone focuses on the nu

Life sciences thrive on innovation, and licensing is the backbone of bringing that innovation to market. But here’s the thing: license agreements are often seen as dense legal documents, full of jargon and clauses that seem unnecessary. Yet, these agreements are critical for defining how intellectual property (IP) is shared, protected, and commercialized. Get them wrong, and you’re looking at disputes, lost revenue, or even legal battles. So, what makes these agreements so tr

If your company is building its own large language model (LLM) for applications like drug discovery, biomarker identification, or clinical trial optimization, this case should be on your radar. A recent ruling by the Munich Regional Court (LG München v. 11.11.2025 – 42 O 14139/24 – GEMA vs. Open AI) —while not yet legally binding—sends a clear signal: training LLMs on protected works constitutes copyright infringement under German law, unless narrow legal exceptions apply . T

Licensing is one of the most powerful tools in the life sciences industry - yet no two deals look the same. Whether you’re a biotech...